The use of combined recombinant interferon alpha-2b medications in the treatment of allergic rhinitis

DOI: https://doi.org/10.29296/25877305-2021-03-13
Download full text PDF
Issue: 
3
Year: 
2021

Professor D. Trukhan(1), Dr Med. Sci.; V. Alekseenko(2); N. Kalashnikova(2); V. Minaeva(1); O.
Shelyapina(1); Professor K. Nesterova(1), Dr Med. Sci.; N. Bagisheva(1), Cand. Med. Sci.; Professor A.
Mordyk(1), Dr Med. Sci.; V. Goloshubina(1), Cand. Med. Sci.; M. Moiseeva(1), Cand. Med. Sci.; O. Vins(3), E.
Nebesnaya(1) (1)Omsk State Medical University (2)Omsk City Polyclinic No.12 (3)Medical and Sanitary
Department, Ministry of Internal Affairs of Russia, Omsk Region

Objective: to present the experience with combined recombinant interferon alpha-2b medications for the topical treatment of seasonal allergic rhinitis (AR) exacerbations. Materials and Methods: The study design was a simple prospective one. This study was conducted on the basis of the Department of Allergology and Immunology of the Omsk City Polyclinic No. 12. The study involved 100 patients who had consulted an allergist about allergic rhinitis (AR) exacerbations - men and women aged 18 to 55 years, mean age (Me 25;75) – 33.0 (28;47) years. There were two consecutive groups of patients: those with acute non-severe seasonal AR and those with acute moderate-to-severe seasonal AR. A group of patients with non-severe AR (group 1; n=50) used the combined interferon-based medication Allergoferon (gel) to treat the disease in the acute phase. A group of patients with moderate-to-severe AR (group 2; n=50) used Allergoferon beta (nasal and eye drops) for the disease treatment in the acute phase. The patients’ conditions were assessed during follow-up examinations on the 7th (visit 2) and 14th (visit 3) days of treatment. Subjective symptoms were evaluated by the questionnaire-based method. This helped to determine the treatment effectiveness as well as the presence and severity of side effects. The effectiveness was assessed based on the reduction in the severity of local and general reactions. Tolerability of the medications was determined according to the patient’s subjective assessment. Results: Control examinations of patients in both groups were conducted on the 7th and 14th days of treatment. On the 7th day of treatment the patients in both groups reported improvement: in the group 1 (patients with non-severe AR) symptoms resolution was noted by 50% of patients, in the group 2 (patients with moderate-to-severe AR) – by 80%. In the group 1 some patients had nasal congestion (50%), eyelids itching (50%), nasal discharge (40%) and sneezing (50%), but the severity of these symptoms (in points) significantly decreased. In the group 2 some patients had the following symptoms: nasal congestion (38%), nasal discharge (31%), sneezing (20%) and eyelids itching (25%), but they reported much less severe symptoms. Patients in both groups had a significant reduction in the severity of all symptoms (nasal congestion, eyelids itching, nasal discharge, sneezing). No side effects were reported. Conclusion: During our study it was noted that both examined interferon-based medications (Allergoferon and Allergoferon Beta) allowed us to achieve a relief of subjective and objective symptoms of AR. In both groups a good tolerability of these medications was noted, no side effects and no cases of withdrawal or refusal were observed.
Keywords: 
interferon-based medications
Allergoferon
Allergoferon Beta
allergic rhinitis
treatment

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniju allergicheskogo rinita. Rossijskaja assotsiatsija allergologov i klinicheskih immunologov. M., 2018; 18 s. [Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu allergicheskogo rinita. Rossiiskaya assotsiatsiya allergologov i klinicheskikh immunologov. M., 2018; 18 s. (in Russ.)]. URL: https://raaci.ru/
  2. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126 (3): 466–76. DOI: 10.1016/j.jaci.2010.06.047
  3. Dyneva M.E., Kurbacheva O.M. Allergicheskij rinit – aktual'naja problema XXI veka. Consilium Medicum. 2019; 21 (3): 65–8 [Dyneva M.E., Kurbacheva O.M. Allergic rhinitis – the actual problem of the XXI century. Consilium Medicum. 2019; 21 (3): 65–8 (in Russ.)]. DOI: 10.26442/20751753.2019.3.190268
  4. Allergologija. Federal'nye klinicheskie rekomendatsii. Pod red. akad. R.M. Haitov, N.I. Il'ina. M.: Farmarus Print Media, 2014; 126 c. [Allergologiya. Federal’nye klinicheskie rekomendatsii. Pod red. akad. R.M. Khaitov, N.I. Il’ina. M.: Farmarus Print Media, 2014; 126 s. (in Russ.)]. URL: http://docplayer.ru/27067887-Allergologiya-federalnye-klinicheskie-rekomendacii-glavnye-redaktory-akad-ran-r-m-haitov-prof-n-i-ilina.html
  5. Akhouri S., House S.A. Allergic Rhinitis. 2020 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available at: https://pubmed.ncbi.nlm.nih.gov/30844213/
  6. Kurbacheva O.M., Pol'ner S.A., Smirnov D.S. Allergicheskij rinit. Vechnaja problema i ee reshenie. Meditsinskij sovet. 2015; 3: 84–90 [Kurbacheva O.M., Polner S.A., Smirnov D.S. Allergic rhinitis. Perpetual problem and current solutions. Meditsinskiy sovet = Medical Council. 2015; 3: 84–91 (in Russ.)]. DOI: 10.21518/2079-701X-2015-3-84-91
  7. Allergic rhinitis. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=allergic+rhinitis&filter=datesearch.y_10 (data obraschenija: 05.11.2020)
  8. Brożek J.L., Bousquet J., Agache I. Et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140 (4): 950–8. DOI: 10.1016/j.jaci.2017.03.050
  9. Lopatin A.S. Rinit: rukovodstvo dlja vrachej. M.: GEOTAR-Media, 2010; 424 s. [Lopatin A.S. Rinit: rukovodstvo dlya vrachei. M.: GEOTAR-Media, 2010; 424 s. (in Russ.)] URL: http://www.geotar.ru/lots/Q0112514.html
  10. Il'ina N.I., Latysheva T.V., Pol'ner S.A. et al. Allergicheskij rinit. Modul'. M.: GEOTAR-Media, 2015 [Il’ina N.I., Latysheva T.V., Pol’ner S.A. et al. Allergicheskii rinit. Modul’. M.: GEOTAR-Media, 2015 (in Russ.)]. URL: https://library.geotar.ru/book/07-MOD-0517.html
  11. Nadej E.V., Nesterova K.I., Programmirovanie techenija i stepeni tjazhesti atopicheskih allergicheskih zabolevanij dyhatel'nyh putej. Omskij nauchnyj vestnik. 2014; 2 (134): 41–5 [Nadei E.V., Nesterova K.I., Programmirovanie techeniya i stepeni tyazhesti atopicheskikh allergicheskikh zabolevanii dykhatel’nykh putei. Omskii nauchnyi vestnik. 2014; 2 (134): 41–5 (in Russ.)].
  12. Nadej E.V., Nechaeva G.I., Sovalkin V.I. Nekotorye aspekty epidemiologii allergicheskih zabolevanij v uslovijah zapadnoj Sibiri. V sb.: Buduschee – za patsientorentirovannoj kardiologiej. Mat-ly VII s'ezda kardiologov Sibirskogo federal'nogo okruga sovmestno s VII Vseross. nauchno-prakt. konf. 2017; s. 96–7 [Nadei E.V., Nechaeva G.I., Sovalkin V.I. Nekotorye aspekty epidemiologii allergicheskikh zabolevanii v usloviyakh zapadnoi Sibiri. V sb.: Budushchee – za patsientorentirovannoi kardiologiei. Mat-ly VII s»ezda kardiologov Sibirskogo federal’nogo okruga sovmestno s VII Vseross. nauchno-prakt. konf. 2017; s. 96–7 (in Russ.)].
  13. Nadej E.V., Sovalkin V.I., Nesterova K.I. i dr. Effektivnost' kombinirovannoj protivovospalitel'noj terapii i allergenspetsificheskoj immunoterapii komorbidnoj allergicheskoj bronhial'noj astmy: odnofaktornyj dispersionnyj analiz. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (3): 87–95 [Nadey E.V., Sovalkin V.I., Nesterova K.I. et al. Efficiency of combined anti-inflammatory therapy and allergenspecific immunotherapy of comorbidity allergic bronchial asthma: one-factor dispersion analysis. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (3): 87–95 (in Russ.)].
  14. Nesterova A.A., Drachuk A.I., Odarchenko I.N. i dr. Allergoferon, kak preparat vybora v lechenii allergicheskogo rinita. V sb.: Nauchno-prakt. konf., posvjasch. 95-letiju Omskoj oblastnoj klinicheskoj bol'nitsy. Sb. tr. konf. 2015; s. 356–7 [Nesterova A.A., Drachuk A.I., Odarchenko I.N. et al. Allergoferon, kak preparat vybora v lechenii allergicheskogo rinita. V sb.: Nauchno-prakt. konf., posvyashch. 95-letiyu Omskoi oblastnoi klinicheskoi bol’nitsy. Sb. tr. konf. 2015; s. 356–7 (in Russ.)].
  15. Nesterova K.I., Ljapin V.A., Kazakovtsev V.P. i dr. Osobennosti pokazatelej mestnogo immuniteta slizistoj obolochki nosa u zdorovyh ljudej krupnogo promyshlennogo tsentra. Rossijskij immunologicheskij zhurnal. 2015; 9 (1): 134–7 [Nesterova K.I., Liapin V.A., Kazakovtsev V.P. et al. Local immunity of the nasal mucosa in healthy people of a large industrial center. Rossiiskii immunologicheskii zhurnal. 2015; 9 (1): 134–7 (in Russ.)].
  16. Truhan D.I., Bagisheva N.V., Alekseenko V.A. Aktual'nye aspekty diagnostiki i lechenija atopicheskoj bronhial'noj astmy. Terapija. 2017; 8 (18): 53–62 [Trukhan D.I., Bagisheva N.V., Alekseenko V.A. Actual aspects of diagnosis and treatment of atopic bronchial asthma. Therapy. 2017; 8 (18): 53–62 (in Russ.)].
  17. Truhan D.I., Filimonov S.N., Bagisheva N.V. Bolezni organov dyhanija: aktual'nye aspekty diagnostiki i lechenija. Novokuznetsk, 2020; 227 s. [Trukhan D.I., Filimonov S.N., Bagisheva N.V. Bolezni organov dykhaniya: aktual’nye aspekty diagnostiki i lecheniya. Novokuznetsk, 2020; 227 s. (in Russ.)]. URL: https://www.elibrary.ru/item.asp?id=41882462
  18. Nesterova K.I., Nesterova A.A. Topicheskaja terapija allergicheskogo rinita. V knige: Mat-ly V Peterburgskogo foruma otorinolaringologov Rossii i IV vseross. kongr. po sluhovoj implantatsii s mezhdunar. uchast. 2016; s. 303–4 [Nesterova K.I., Nesterova A.A. Topicheskaya terapiya allergicheskogo rinita. V knige: Mat-ly V Peterburgskogo foruma otorinolaringologov Rossii i IV vseross. kongr. po slukhovoi implantatsii s mezhdunar. uchast. 2016; s. 303–4 (in Russ.)].
  19. Terehova E.P., Terehov D.V. Allergicheskij rinit: sovremennye metody terapii. Meditsinskij sovet. 2016; 17: 74–9 [Terekhova E.P., Terekhov D.V. Allergic rhinitis: modern methods of treatment. Meditsinskiy sovet = Medical Council. 2016; 17: 74–9 (in Russ.)]. DOI: 10.21518/2079-701X-2016-17-74-79
  20. Rjazantsev S.V., Goncharov O.I. Allergicheskij rinit. Meditsinskij sovet. 2018; 20: 76–9 [Ryazantsev S.V., Goncharov O.I. Allergic rhinitis. Meditsinskiy sovet = Medical Council. 2018; 20: 76–9 (in Russ.)]. DOI: 10.21518/2079-701X-2018-20-76-79
  21. Brożek J.L., Bousquet J., Agache I. Et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140 (4): 950–8. DOI: 10.1016/j.jaci.2017.03.050
  22. Bousquet J., Hellings P.W., Agache I. et al. Mobile Airways Sentinel Network (MASK) Study Group. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019; 143 (3): 864–79. DOI: 10.1016/j.jaci.2018.08.049
  23. Bousquet J., Schünemann H.J., Togias A. et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020; 145 (1): 70–80.e3. DOI: 10.1016/j.jaci.2019.06.049
  24. Gonzales-van Horn S.R., Farrar J.D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185–94. DOI: 10.1189/jlb.3RU0315-099R
  25. Huber J.P., Gonzales-van Horn S.R., Roybal K.T. et al. IFN-Suppresses GATA3 Transcription from a Distal Exon and Promotes H3K27 Trimethylation of the CNS-1 Enhancer in Human Th2 Cells. J Immunol. 2014; 192 (12): 5687–94. DOI: 10.4049/jimmunol.1301908
  26. Gonzales-van Horn S.R., Farrar J.D. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015; 98 (2): 185–94. DOI: 10.1189/jlb.3RU0315-099R4
  27. Gaponjuk P.Ja. Novyj podhod k lecheniju bol'nyh s allergicheskim rinitom. Allergologija i immunologija. 2008; 9: 277 [Gaponyuk P.Ya. Novyi podkhod k lecheniyu bol’nykh s allergicheskim rinitom. Allergologiya i immunologiya. 2008; 9: 277 (in Russ.)].
  28. Sidhu G., Akhondi H. Loratadine. 2020 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK542278/
  29. Braido F., Sclifò F., Ferrando M. et al. New therapies for allergic rhinitis. Curr Allergy Asthma Rep. 2014; 14 (4): 422. DOI: 10.1007/s11882-014-0422-z
  30. Xiao J., Wu W.X., Ye Y.Y. et l. A Network Meta-analysis of Randomized Controlled Trials Focusing on Different Allergic Rhinitis Medications. Am J Ther. 2016; 23 (6): e1568–e1578. DOI: 10.1097/MJT.0000000000000242
  31. Seresirikachorn K., Khattiyawittayakun L., Chitsuthipakorn W. et al. Antihistamines for treating rhinosinusitis: systematic review and meta-analysis of randomised controlled studies. J Laryngol Otol. 2018; 132 (2): 105–10. DOI: 10.1017/S002221511700192X
  32. Shen C., Chen F., Wang H. et al. Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels. Braz J Otorhinolaryngol. 2020; 86 (1): 63–73. DOI: 10.1016/j.bjorl.2018.09.007
  33. Scadding G.K. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Allergy. 2000; 55 (Suppl. 62): 19–23. DOI: 10.1034/j.1398-9995.2000.055suppl62019.x
  34. Snyman J.R., Potter P.C., Groenewald M. et al. Claricort Study Group. Effect of betamethasone-loratadine combination therapy on severe exacerbations of allergic rhinitis: a randomised, controlled trial. Clin Drug Investig. 2004; 24 (5): 265–74. DOI: 10.2165/00044011-200424050-00003
  35. Tillmann H.C., Stuck B.A., Feuring M. et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest. 2004; 34 (1): 67–73. DOI: 10.1111/j.1365-2362.2004.01293.x
  36. Mendoza de Morales T., Sánchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J. 2009; 2 (4): 49–53. DOI: 10.1097/WOX.0b013e31819f2105
  37. Strayer D.R., Carter W.A. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res. 2012; 32 (3): 95–102. DOI: 10.1089/jir.2011.0069
  38. Hmelevskoj V.I., Provotorov V.Ja., Kiseleva V.V. i dr. Al'fa-interferon v klinicheskoj praktike. Arhiv vnutrennej meditsiny. 2014; 5: 34–8 [Khmelevskoi V.I., Provotorov V.Ya., Kiseleva V.V., et al. Al’’fa-interferon v klinicheskoi praktike. The Russian Archives of Internal Medicine. 2014; 5: 34–8 (in Russ.)]. DOI: 10.20514/2226-6704-2014-0-5-34-38
  39. Ndika J., Airaksinen L., Suojalehto H. et al. Epithelial proteome profiling suggests the essential role of interferon-inducible proteins in patients with allergic rhinitis. J Allergy Clin Immunol. 2017; 140 (5): 1288–98. DOI: 10.1016/j.jaci.2017.05.040
  40. Zissler U.M., Schmidt-Weber C.B. Predicting Success of Allergen-Specific Immunotherapy. Front Immunol. 2020; 11: 1826. DOI: 10.3389/fimmu.2020.01826
  41. Nesterova K.I., Nesterova A.A. Effektivnost' topicheskoj antigistaminnoj monoterapii pri manifestatsii sezonnogo allergicheskogo rinita. Vestnik otorinolaringologii. 2015; 80 (4): 77–80 [Nesterova K.I., Nesterova A.A. The effectiveness of topical antihistamine monotherapy in the patients presenting with the manifestations of seasonal allergic rhinitis. Bulletin of Otorhinolaryngology. 2015; 80 (4): 77–80 (in Russ.)]. DOI: 10.17116/otorino201580477-80
  42. Nesterova K.I., Nesterova A.A. Mesto topicheskih antigistaminnyh preparatov pri sezonnom allergicheskom rinite. Dnevnik kazanskoj meditsinskoj shkoly. 2008; 1: 88–92 [Nesterova KI, Nesterova AA. The niche of topical antihistamines in seasonal allergic rhinitis. Dnevnik Kazanskoy Meditsinskoy Shkoly. 2008, 1 (7): 88–92 (in Russ.)].
  43. Sotnikova N.Ju., Pahomova T.V., Lykova T.A. Lechebnaja effektivnost' kombinirovannogo lekarstvennogo preparata Allergoferon® pri persistirujuschem allergicheskom rinite. Rossijskij allergologicheskij zhurnal. 2016; 1: 52–6 [Sotnikova N.Y., Pachomova T.V., Lykova T.A. Treatment efficacy of the combined medication Allergoferon® during persistent allergic rhinitis. Rossiiskii allergologicheskii zhurnal. 2016; 1: 52–6 (in Russ.)].
  44. Rjabtseva A.A., Sotnikova N.Ju., Chumikov O.V. i dr. Otsenka effektivnosti i bezopasnosti novogo kombinirovannogo preparata s rekombinantnym interferonom i betametazonom pri obostrenii pollinoza. Oftal'mologija. 2016; 3: 197–204 [Ryabtseva A.A., Sotnikova N.Y., Chumikov O.V. et al. Efficacy and safety of a new combined medication with recombinant interferon and betamethasone in the treatment of hay fever during periods of exacerbation. Ophthalmology in Russia. 2016; 13 (3): 197–204 (in Russ.)]. DOI: 10.18008/1816-5095-2016-3-197-204
  45. Sotnikova N.Ju. Novye vozmozhnosti v lechenii allergicheskogo rinita i allergicheskogo kon'junktivita: topicheskie preparaty. Infektsionnye bolezni: novosti, mnenija, obuchenie. 2017; 1: 42–50 [Sotnikova N.Yu. New perspectives in the treatment of allergic rhinitis and conjunctivitis: topical medications. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2017; 1: 42–50 (in Russ.)].
  46. Nazarova E.V. Novye vozmozhnosti kombinirovannoj terapii allergicheskogo rinita v uslovijah real'noj klinicheskoj praktiki. Rossijskij allergologicheskij zhurnal. 2019; 1-1: 85–9 [Nazarova E.V. New opportunities for the combined therapy of allergic rhinitis in real clinical practice. Rossiiskii allergologicheskii zhurnal. 2019; 1-1: 85–9 (in Russ.)].
  47. Truhan D.I., Lebedev O.I. Izmenenie organa zrenija pri somaticheskih zabolevanijah. Ter arh. 2015; 87 (8): 132–6 [Trukhan D.I., Lebedev O.I. Change in the organ of vision in somatic diseases. Therapeutic Archive. 2015; 87 (8): 132–6 (in Russ.)]. DOI: 10.17116/terarkh2015878132-136
  48. Surov A.V., Zaspina A.G. Opyt primenenija lekarstvennogo preparata interferon al'fa-2b v sochetanii s loratadinom v vide gelja dlja mestnogo i naruzhnogo primenenija v kompleksnoj terapii allergicheskih zabolevanij glaz. Oftal'mologija. 2014; 11 (1): 62–5 [Surov, A.V., Zaspina A.G. Complex treatment of allergic eye diseases using interferon alfa-2b and loratadine gel for topical and external use. Ophthalmology in Russia. 2014; 11 (1):62–5 (in Russ.)]. DOI: 10.18008/1816-5095-2014-1-62-65
  49. Truhan D.I., Fedotova O.I., Pilipenko A.V. i dr. Opyt primenenija preparata Allergoferon® pri ukusah nasekomyh. Effektivnaja farmakoterapija. 2020; 16 (8): 10–7 [Trukhan D.I., Fedotova O.I., Pilipenko A.V. et al. The Experience of the Medication Allergoferon® in the Treatment of Insect Bites. Effektivnaya farmakoterapiya. 2020; 16 (8): 10–7 (in Russ.)]. DOI: 10.33978/2307-3586-2020-16-8-10-17